Strata Critical Medical (SRTA) Cost of Revenue (2021 - 2026)

Strata Critical Medical (SRTA) has reported Cost of Revenue for 6 consecutive years, with $53.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cost of Revenue rose 84.35% year-over-year to $53.3 million; the TTM figure through Mar 2026 stood at $199.1 million (up 41.82% YoY), while the FY2025 annual figure was $156.0 million, up 33.09% from the prior year.
• Cost of Revenue eased to $53.3 million in Q1 2026 per SRTA's latest filing, from $55.1 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $55.9 million in Q3 2023 and bottomed at $23.7 million in Q1 2022.
• Historically, Cost of Revenue has averaged $42.8 million across 5 years, with a median of $41.4 million in 2024.
• Annual changes were most pronounced in 2022 — Cost of Revenue jumped 443.59% — and 2024, when it sank 48.89%.
• Strata Critical Medical's Cost of Revenue stood at $54.2 million in 2022, then retreated by 29.06% to $38.5 million in 2023, then retreated by 18.44% to $31.4 million in 2024, then jumped by 75.68% to $55.1 million in 2025, then fell by 3.36% to $53.3 million in 2026.
• Business Quant data shows SRTA's Cost of Revenue at $53.3 million in Q1 2026, $55.1 million in Q4 2025, and $37.7 million in Q3 2025.